1. - Clinica malattie apparato respiratorio
1. - Clinica malattie apparato respiratorio
1. - Clinica malattie apparato respiratorio
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
IL VOLTO DELLA BPCO CHE CAMBIA ● QUADERNO 6<br />
1<strong>1.</strong> Jarvis B e Markham A: Inhaled salmeterol: a review<br />
of its efficacy in chronic obstructive pulmonary disease.<br />
Drugs Aging 2001; 18:441-472.<br />
12. Rossi A, Kristufek P, Levine BE et al: Comparison<br />
of the efficacy, tolerability, and safety of formoterol<br />
dry powder and oral, slow-release theophylline in<br />
the treatment of COPD. Chest 2001; 121:1058-<br />
1069.<br />
13. ZuWallack RL, Mahler DA, Reilly D et al: Salmeterol<br />
plus theophylline combination therapy in the<br />
treatment of COPD. Chest 2001; 119:1661-1670.<br />
14. No Author listed: Routine nebulized ipratropium<br />
and albuterol together are better than either alone<br />
in COPD.The COMBIVENT Inhalation Solution<br />
Study Group Chest 1997; 112:1514-152<strong>1.</strong><br />
15. Bourbeau J, Rouleau MY, Boucher S: Randomised<br />
controlled trial of inhaled corticosteroids in patients<br />
with chronic obstructive pulmonary disease. Thorax<br />
1998, 53:477-482.<br />
16. Burge PS, Calverley PM, Jones PW et al: Randomised,double<br />
blind,placebo controlled study of fluticasone<br />
propionate in patients with moderate to<br />
severe chronic pbstructive pulmonary disease: the<br />
ISOLDE trial. BMJ 2000; 320:1297-1303.<br />
17. Burge S: Should inhaled corticosteroids be used in<br />
the long term treatment of chronic obstructive pulmonary<br />
disease Drugs 2001; 61:1535-1544.<br />
18. van der Boom G, Rutten-van Molken MP, Molema<br />
J et al:The cost effectiveness of early treatment<br />
with fluticasone propionate 250 microg twice a day<br />
in subjects with obstructive airway disease. Results<br />
of the DIMCA program. Am J Respir Crit Care<br />
Med 2001; 164:2057-2066.<br />
19. O’Brien A, Russo-Magno P, Karki A et al: Effects<br />
of withdrawal of inhaled steroids in men with severe<br />
irreversibile airflow obstruction. Am J Respir<br />
Crit Care Med 2001; 164:365-37<strong>1.</strong><br />
20. van der Valk P, Monninkhof E, van der Palen J et<br />
al: Effects of discontinuation of inhaled corticosteroids<br />
in patients with Chronic Obstructive Pulmonary<br />
Disease. The COPE Study. Am Rev Respir<br />
Crit Care Med 2002; 166:1358-1363.<br />
2<strong>1.</strong> Antonelli Incalzi R, Bellia V, Catalano F et al: Evaluation<br />
of health outcomes in elderly patients with<br />
asthma and COPD using disease-specific and generic<br />
instruments.The Salute Respiratoria nell’Anziano<br />
(Sa.R.A.) Study. Chest 2001; 120:734-742.<br />
22. Di Lorenzo G, Morici G, Drago A et al: Efficacy,<br />
tolerability, and effects on quality of life of inhaled<br />
salmeterol and oral theophylline in patients with<br />
mild-to-moderate chronic obstructive pulmonary<br />
disease. SLMT02 Italian study Group. Clin Ther<br />
1998; 20:1130-1148.<br />
23. Kirsten DK, Wegner RE, Jorres RA et al: Effects<br />
of theophylline withdrawal in severe chronic obstructive<br />
pulmonary disease. Chest 1993;<br />
104:1101-1107.<br />
24. Nocturnal oxygen therapy trial group: Continuous<br />
or nocturnal oxygen therapy in hypoxemic chronic<br />
obstructive lung disease. Ann Intern Med 1980;<br />
93:391-398.<br />
25. Intermittent positive pressure trial group: Intermittent<br />
positive pressure breathing therapy of chronic<br />
obstructive pulmonary disease. Ann Int Med 1983;<br />
99:612-620.<br />
26. Bergner M, Bobbit RA, Carter WB et al:The Sickness<br />
Impact Profile: development and final revision<br />
of a health status measure. Med Care 1981; 19:787-<br />
805.<br />
27. Okubadejo AA, Paul EA, Jones PW et al: Does<br />
long-term oxygen therapy affect quality of life in<br />
patients with chronic obstructive pulmonary disease<br />
and severe hypoxaemia Eur Respir J 1996;<br />
9(11):2335-2339.<br />
28. Jones PW, Quirk FH, Baveystock CM et al: A selfcomplete<br />
measure for chronic airflow limitation -<br />
the St. George’s Respiratory Questionnaire. Am<br />
Rev Respir Dis 1992; 145:1321-1327.<br />
29. Carone M, Bertolotti G, Jones PW et al:Analysis of<br />
factors that characterize health impairment in patients<br />
with chronic respiratory failure.Quality of Life<br />
in Chronic Respiratory Failure Group. Eur Respir<br />
J 1999; 13(6):1293-1300.<br />
30. Stewart AL, Hays RD, Ware JE: The MOS Short<br />
Form General Health Survey: reliability and validity<br />
in a patient population. Med Care 1988;<br />
26:724-732.<br />
3<strong>1.</strong> Simonds AK e Elliot MW: Outcome of domiciliary<br />
nasal intermittent positive pressure ventilation in restrictive<br />
and obstructive disorders. Thorax 1995;<br />
50:604-609.<br />
32. Crockett AJ, Cranston JM, Moss JR et al:The MOS<br />
SF-36 health survey questionnaire in severe chronic<br />
airflow limitation: comparison with the Nottingham<br />
Health Profile. Qual Life Res 1996;<br />
5(3):330-338.<br />
33. Perrin C, El Far Y,Vandenbos F et al: Domiciliary<br />
nasal intermittent positive pressure ventilation in se-<br />
44
Change language